WASHINGTON D.C. – In a stunning display of bureaucratic agility, the Food and Drug Administration (FDA) announced today it would reconsider Moderna’s application for its novel influenza vaccine, just over a week after flatly refusing to entertain it. The abrupt about-face, sources indicate, was prompted by the discovery of a misplaced pair of reading glasses.

“It turns out, the initial rejection letter was drafted while Dr. Evelyn Piffle, our Chief of Advanced Pharmaceutical Scrutiny, was searching for her bifocals,” explained FDA spokesperson Bartholomew 'Barty' Crumple, clutching a large magnifying glass. “She simply couldn’t make out the fine print on page 3,742 of the submission, which, as we now know, contained the critical data point regarding ‘enhanced avian immunity in laboratory-grade pigeons.’”

Moderna CEO, Dr. Quentin Quibble, expressed cautious optimism. “We are thrilled the FDA has located its eyewear,” he stated. “We believe our vaccine, which harnesses the power of genetically modified plankton, will revolutionize seasonal sniffles, provided they can now read the efficacy charts.”

Dr. Piffle, reached for comment, reportedly squinted at a reporter’s badge before muttering, “What was the question again? Is this about the new kale regulations?” The FDA assures the public that all future pharmaceutical decisions will be made with 20/20 vision, or at least with corrective lenses securely fastened.